Cameco vs. Denison: Which Uranium Stock Has an Edge Right Now?
CCJ offers scale, stable production and long-term contracts, while DNN brings higher-risk, higher-reward potential.
Zacks
CCJ's Adjusted EBITDA Fell 42% in Q226: Is There a Recovery Ahead?
Cameco's Q2 results weaken as lower uranium sales and Westinghouse earnings weigh on growth, but firm uranium prices support its longer-term outlook.
Zacks
3 Nuclear Stocks With Real Revenue vs. 3 That Are Still Pre-Revenue. Here's Where the Money Actually Is.
Key PointsConstellation, BWX, and Cameco already generate billions from nuclear power, equipment, and fuel...
Nasdaq News: Markets
Should You Buy, Hold or Sell UUUU Stock Post Q2 Earnings?
Energy Fuels' uranium growth and rare earth expansion offer long-term potential, but a stretched valuation and expected 2026 loss weigh on its near-term appeal.
Zacks
Cameco vs. Uranium Energy: Which Uranium Stock Wins the Nuclear Restart?
Key PointsCameco's scale and steady growth make it a reliable play on nuclear energy...
Nasdaq News: Markets
Why Cameco's Ugly Earnings Miss Might Be Good News in Disguise
Key PointsCameco's earnings missed expectations largely due to Westinghouse...
Nasdaq News: Markets
Cameco (CCJ) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Cameco Gains 7% Despite Q2 Earnings Miss: How to Play the Stock?
CCJ shares jump 7% despite a Q2 earnings miss, as investors weighed Westinghouse IPO plans, resilient guidance and a stretched valuation.
Zacks
LEU's Q2 Earnings Beat, Revenues up Y/Y on Strong Uranium Sales
Centrus Energy beats Q2 earnings and revenue estimates, but higher administrative and technology costs sharply compress margins.
Zacks